As Roche plugs away at its anti-amyloid treatment for Alzheimer’s disease, it’s adding a tau-targeting treatment to the mix. The Swiss pharma is handing over $120 million upfront for the right to develop UCB’s anti-tau antibody. If all goes to plan, milestone payments and royalties could bring the deal’s total close to $2 billion. The drug, UCB0107, is designed to block or reduce the buildup of tau proteins in the brain that lead to nerve cell damage and death. Source: Fierce Biotech 29/7/2020